https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Demographic, clinical, psychosocial, and environmental correlates of objectively assessed physical activity among breast cancer survivors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25371 Wed 24 Nov 2021 15:50:36 AEDT ]]> Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41392 Tue 02 Aug 2022 17:47:29 AEST ]]> Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20479 Sat 24 Mar 2018 07:59:08 AEDT ]]> The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28140 Sat 24 Mar 2018 07:36:38 AEDT ]]> Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33527 difference_in_effect = 0.13, 95%CI = 0.03;0.22) and PF (βdifference_in_effect = 0.10, 95%CI = 0.01;0.20) were significantly larger for supervised than unsupervised interventions. In conclusion, exercise, and particularly supervised exercise, effectively improves QoL and PF in patients with cancer with different demographic and clinical characteristics during and following treatment. Although effect sizes are small, there is consistent empirical evidence to support implementation of exercise as part of cancer care.]]> Fri 03 Dec 2021 10:34:03 AEDT ]]> Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34907 interaction = -1.3 s, 95% confidence interval [CI] -2.6 to 0.0), whole-body lean mass (ßinteraction = 1194 g, 95% CI 234 to 2153) and ASM mass (ßinteraction = 562 g, 95% CI 49 to 1075), and approached significance for fat mass (ßinteraction = -1107 g, 95% CI -2346 to 132), with greater benefits for men previously on long-term ADT. At 6 months, the intervention effects on chair rise time -1.5 s (95% CI -2.5 to -0.5), whole-body lean mass 824 g (95% CI 8 to 1640), ASM mass 709 g (95% CI 260 to 1158), and fat mass -1377 g (95% CI -2156 to -598) were significant for men previously on long-term ADT, but not for men on short-term ADT. At 12 months, the intervention effects for men on long-term ADT remained significant for the chair rise, with improved performance (-2.0 s, 95% CI -3.0 to -1.0) and increased ASM (537 g, 95% CI 153 to 921). Time on ADT did not moderate the exercise effects on muscle strength, nor did time since ADT cessation moderate any intervention effects. Similarly, testosterone and baseline values of the outcome had negligible moderator effects. Conclusions: Men with PCa previously treated long-term with ADT respond more favourably to exercise in terms of lower body muscle performance and body composition (lean and fat mass, and ASM) than those with short-term ADT exposure. As a result, men who were formerly on long-term androgen suppression regimens should be especially prescribed exercise medicine interventions to alleviate residual treatment-related adverse effects.]]> Fri 01 Apr 2022 09:25:19 AEDT ]]>